Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1CNS 1

Conditions

Oligodendroglioma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Lopinavir × Clear all
NCT04455958 2021-04-26

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

OHSU Knight Cancer Institute

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT01095094 2013-06-10

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Case Comprehensive Cancer Center

Phase 2 Terminated
19 enrolled 9 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡